Stem Cell-derived Treatment One Step Closer to Type 1 Diabetes Cure
San Diego biotech working on 'functional cure' for type 1 diabetes sold to rival for $320M - The San Diego Union-Tribune
CRISPR and ViaCyte Dose First Patient in Historic Type 1 Diabetes Trial | BioSpace
ViaCyte cure for diabetes. Most promising research – Fixic Patch
ViaCyte Secures $80 Million Financing to Advance Functional Cures for Insulin-Requiring Diabetes
Costing out a cure – Eric Bender
ViaCyte's Sweet Three-Pronged Attack against Type 1 Diabetes
Stem Cell Implants Could Cure Diabetes | Healthcare Packaging
ViaCyte and CRISPR Introduce New Stem Cell Therapy for Type 1 Diabetes
ViaCyte Overview: T1D Practical Cure Progress : 2022 Reports : Report Library : Publications : Juvenile Diabetes Cure Alliance (JDCA)
ViaCyte's Future 'Functional Diabetes Cure' for Diabetes
A Cure for Type 1 Diabetes? A Look at the Most Promising Research - Diabetes Strong
Johnson & Johnson, ViaCyte testing possible diabetes cure
Filming the ViaCyte Type 1 Cell Experiment | Insulin Nation
Vertex to acquire stem cell-derived diabetes treatment maker ViaCyte
Vertex buys ViaCyte for $320M, clearing out T1D competition
Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes
ViaCyte's Future 'Functional Diabetes Cure' for Diabetes
Vertex Acquires ViaCyte, Combining Resources Toward a T1D Cure
Will ViaCyte's Encaptra Cell Delivery System 'Cure' Type 1 Diabetes? | Insulin Nation
Exciting news: stem cell-based treatments producing insulin in participants with type 1 diabetes | JDRF Canada
ViaCyte Acquires Rights to BetaLogics Assets
CRISPR Therapeutics and ViaCyte Tackling Type 1 Diabetes - YouTube
